MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Galena Biopharma (GALE) Pipeline Hailed As “Rich” Investment By Seeking Alpha Contributor 0 comments
    Dec 3, 2013 2:40 PM | about stocks: GALE

    Shares of Galena Biopharma have soared 99 percent higher in the last month, as Seeking Alpha contributor "Stock Investor" notes in his bullish article on the company. The author attributes the rally to increased investor interest as Galena displays its potential as a buyout target.

    To read the full article visit seekingalpha.com/article/1870351

    Highlighting Galena's main drug candidate, breast cancer therapy NeuVax, Stock Investor provides a short video sourced from the company's website demonstrating how the therapy works.

    The article also recaps and highlights the value of Galena's Folate Binding Protein (NYSE:FBP) vaccine, noting the importance of phase 1 results. In recent phase 1 trial of FBP it was determined that optimal dosage was 500 mcg peptide combined with 250 mcg GM-CSF. The vaccine proved to be well-tolerated and Galena anticipates initiating a phase 2 trial in December.

    Stock Investor also discusses additional therapeutic application for Neuvax, Galena's most recent financial results, and the market potential of Abstral® for breakthrough cancer pain.

    "If Abstral were only able to gain 10 percent of the potential U.S. market for TIRFs it would bring in $40 million in revenue. With a 30 percent profit margin based on initial sales, this could bring upwards of $12 million per year in profits to GALE and reduce its need for additional financing," he writes.

    In his conclusion the author writes, "Galena is one of the most interesting biotechnology investments I have uncovered this year. The market potential for the numerous indications the company is focused on is huge. The launch of Abstral in the U.S. will help to fund the GALE pipeline and could have the potential to be a large revenue generator all by itself based on the gains seen in INSY over the last year."

    For more information, visit galenabiopharma.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: GALE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.